Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen

Jian Yan, Dawn K. Reichenbach, Natasha Corbitt, David A. Hokey, Mathura P. Ramanathan, Kibwei A. McKinney, David B. Weiner, Duane Sewell

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

Human papillomavirus type 16 (HPV-16) infection is associated with a majority of cervical cancers and a significant proportion of head and neck cancers. Here, we describe a novel-engineered DNA vaccine that encodes a HPV-16 consensus E6/E7 fusion gene (pConE6E7) with the goal of increasing its antitumor cellular immunity. Compared to an early stage HPV-16 E7 DNA vaccine (pE7), this construct was up to five times more potent in driving E7-specific cellular immune responses. Prophylactic administration of this vaccine resulted in 100% protection against HPV E6 and E7-expressing tumors. Therapeutic studies indicated that vaccination with pConE6E7 prevented or delayed the growth of tumors. Moreover, immunization with pConE6E7 could also partially overcome immune tolerance in E6/E7 transgenic mice. Such DNA immunogens are interesting candidates for further study to investigate mechanisms of tumor immune rejection in vivo.

Original languageEnglish (US)
Pages (from-to)431-440
Number of pages10
JournalVaccine
Volume27
Issue number3
DOIs
StatePublished - Jan 14 2009

Keywords

  • DNA vaccine
  • E6 and E7 protein
  • HPV-16

Fingerprint Dive into the research topics of 'Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen'. Together they form a unique fingerprint.

Cite this